[驱动基因阴性非小细胞肺癌患者脑转移免疫治疗的研究进展]
[Research Progress of Immunotherapy for Brain Metastases in Patients with Drive Gene Negative NSCLC].
作者信息
Zhang Shuang, Liu Jingjing, Yang Changliang, Li Shuang, Cheng Ying
机构信息
Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):610-614. doi: 10.3779/j.issn.1009-3419.2018.08.06.
Brain metastasis was a common metastasis site and leading cause of death in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors had improved survival of NSCLC patients with positive drive gene. It also brings good news to NSCLC patients with positive drive gene and brain metastases. However, there is still no effective treatment for NSCLC patients with drive gene-negative and brain metastases. In recent years, immunotherapy has made breakthrough progress and become important first and second line treatment options of NSCLC especially in patients with drive gene-negative. The role of immunotherapy in specific populations of NSCLC-brain metastasis patients, especially drive gene-negative patients has become the focus of attention. In this report, we review the research progress of immunotherapy in NSCLC with brain metastases, especially in driver-negative patients, analyze the limitations of existing research and future challenge. .
脑转移是非小细胞肺癌（NSCLC）常见的转移部位和主要死因。酪氨酸激酶抑制剂提高了驱动基因阳性的NSCLC患者的生存率。这也给驱动基因阳性且有脑转移的NSCLC患者带来了好消息。然而，对于驱动基因阴性且有脑转移的NSCLC患者仍没有有效的治疗方法。近年来，免疫疗法取得了突破性进展，成为NSCLC重要的一线和二线治疗选择，尤其是在驱动基因阴性的患者中。免疫疗法在NSCLC脑转移患者的特定人群，尤其是驱动基因阴性患者中的作用已成为关注焦点。在本报告中，我们综述了免疫疗法在伴有脑转移的NSCLC，尤其是驱动基因阴性患者中的研究进展，分析了现有研究的局限性和未来挑战。
Zotero 插件